Inpro

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inpro

Quick Facts

Property Description
Active ingredient Omeprazole
Form Capsules, Enteric-coated Tablets, Powder for Infusion
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Reducing gastric acid production
Origin Synthetic substituted benzimidazole

What Type of Medicine is Inpro?

Inpro is a synthetic medicinal agent that contains the active ingredient Omeprazole, which is classified as a Proton Pump Inhibitor (PPI). This pharmacological class represents a group of compounds developed to reduce the production of stomach acid. Omeprazole itself is chemically categorized as a substituted benzimidazole compound. Inpro is often commercially positioned for a broad adult patient group, and its availability can include both prescription-only (Rx) forms and specific lower-dose Over-The-Counter (OTC) forms.

Composition and Available Forms of Inpro

Inpro is a single-ingredient product featuring Omeprazole as its sole active component, formulated with necessary pharmaceutical excipients for delivery. Due to the acid-sensitive nature of the active compound, oral preparations are typically provided as delayed-release capsules or enteric-coated tablets to protect the Omeprazole from degradation in the stomach. For circumstances where oral intake is not possible, the medication is also available as a sterile powder for intravenous infusion, supporting both oral and intravenous routes of administration. The development of these various forms reflects the clinical need for adaptable acid suppression methods across different patient needs.

General Purpose of Inpro: Controlling Gastric Acidity

The fundamental purpose of Inpro is to achieve a profound and sustained reduction in the acid secreted by the stomach's parietal cells. This is achieved by the drug's mechanism of irreversibly blocking the H^+/K^+-ATPase enzyme, or proton pump, which is the final step in acid creation. This targeted action provides control over gastric acid output, which helps in promoting the healing of the digestive lining. This consistency is vital in managing typical acid-related discomforts.

What side effects are possible with Inpro?

Possible Side Effects and Safety Information

The safety profile of Inpro is characterized by the potential for serious, disabling, and potentially irreversible adverse reactions involving multiple body systems, as documented by governmental regulatory authorities like the FDA and EMA.

Serious Adverse Reactions and Safety Restrictions

Official labels carry a Boxed Warning—the strongest type of caution—regarding these systemic risks, which include:

  • Tendinitis and Tendon Rupture: Inflammation or tearing of a tendon, particularly the Achilles tendon. This risk is higher in patients over 60, those with kidney disease, those with solid organ transplants, and those taking systemic corticosteroids.
  • Peripheral Neuropathy: Nerve damage symptoms such as pain, burning, tingling, numbness, or weakness, which may be long-lasting.
  • Central Nervous System (CNS) Effects: Psychiatric reactions including anxiety, depression, confusion, hallucinations, and suicidal ideation, as well as seizures.
  • Aortic Aneurysm and Dissection: An increased risk of tears or ruptures in the aorta, the body’s main artery.
  • Worsening of Myasthenia Gravis: Can exacerbate muscle weakness in patients with this pre-existing condition.

Due to these risks, regulatory bodies have restricted the use of this drug to specific, serious infections when no other suitable treatment options are available. Treatment must be discontinued immediately upon the first signs of tendon pain, neuropathy symptoms, or CNS effects to prevent potentially permanent injury.

Common and Other Adverse Reactions

Common adverse reactions typically involve the gastrointestinal system, such as nausea and diarrhea, as well as CNS effects like headache and dizziness. Other clinically significant adverse reactions include blood glucose disturbances (hypoglycemia or hyperglycemia), prolongation of the QT interval (a heart rhythm abnormality), severe diarrhea caused by Clostridium difficile infection, and photosensitivity (severe reaction to sun exposure).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation defines the Omeprazole (Inpro) overdose profile based on documented clinical presentations and mandated emergency procedures. Seek immediate medical attention for any suspected overdose to allow for necessary clinical assessment.

Overdose Presentation Official Regulatory Description
Documented Manifestations Symptoms may include confusion, drowsiness, blurred vision, tachycardia (fast heartbeat), headache, nausea, vomiting, diaphoresis (increased sweating), and dry mouth or flushing.
Severity Status Overdose symptoms are generally transient. Regulatory reports indicate that no serious clinical outcome has been reported in cases involving single oral doses up to 900 mg.

Official Management and Treatment Constraints

  • Antidote Status: No specific antidote for omeprazole overdosage is known.
  • Procedural Mandate: Treatment is required to be symptomatic and supportive, addressing the patient’s clinical manifestations as they occur.
  • Dialysis Constraint: Omeprazole is extensively protein bound, meaning it is not readily dialyzable, and procedures such as hemodialysis are not effective in removing the substance.

The overall regulatory profile strictly mandates that urgent medical intervention is required upon suspicion of overdosage. This ensures appropriate supportive measures are implemented, given the absence of a specific antidote and the documented constraints on active drug removal procedures.

Therapeutic Uses of Inpro

Quick Facts on Inpro

  • Support for Prostate Comfort: Assists in managing symptoms associated with acute and long-term prostate affections.
  • Tissue Support: Utilized to support the repair of the anal and rectal mucosa.
  • Relief of Discomfort: May be used as an adjunct to help address localized annoying and painful symptoms in the rectal area, such as those related to hemorrhoids or anal fissures.

Inpro is an agent formulated to provide local support for symptoms linked to conditions affecting the rectal and anal area, as well as the prostate. It may be used as part of a comprehensive management strategy, working alongside prescribed drug therapy, to address associated discomfort and localized tissue health concerns.

The medication is indicated for use in managing certain manifestations of acute and chronic prostate affections. It contributes to symptom management for discomfort and inflammation present in the prostate region.

Additionally, Inpro is utilized to support the healing and recovery of the anal and rectal mucosa. This application helps to relieve localized, painful symptoms connected to anorectal disorders, including hemorrhoids and anal fissures. The components are intended to create a protective environment that facilitates the body’s natural processes of tissue repair and recovery in the affected areas.

Regulatory References

  1. https://medlineplus.gov/analdisorders.html

Eligibility and Restrictions for Use

Population Eligibility and Regulatory Restrictions

Inpro (Omeprazole) eligibility is strictly defined by government regulatory labeling, categorizing which populations may use the medicine and which must be excluded. The medication is approved for use in adults and in pediatric patients between the ages of one and sixteen years for specific labeled indications.

Use is contraindicated in any patient with a known hypersensitivity to the active ingredient or other drugs in the substituted benzimidazole class. Furthermore, regulatory agencies prohibit use in patients concurrently receiving specific antiretroviral agents, such as nelfinavir, due to non-eligibility constraints outlined in the prescribing information.

Special restrictions apply to patients with Hepatic Impairment (liver problems), necessitating caution and potential dose adjustment. Conversely, dose adjustment is generally not required for those with renal impairment. The safety and effectiveness of Inpro have not been established in infants younger than one year of age.

For pregnancy and lactation, the medicine can generally be used, as official documents indicate that adverse effects on the fetus or newborn are not likely when therapeutic doses are administered.

What should I know about interactions with other medicines?

Omeprazole's official interaction profile is structured around two primary mechanisms and several specific regulatory restrictions.

Mandatory Restrictions

Co-administration is formally contraindicated with certain antiretroviral medicines, including Nelfinavir and Rilpivirine, as this combination significantly reduces the plasma concentration of the antiretroviral agents. The use of the herbal product St. John's Wort and the antibiotic Rifampin is advised to be avoided because they may reduce the concentration of Omeprazole itself.

Pharmacokinetic and Pharmacodynamic Effects

Omeprazole is classified as a moderate inhibitor of the CYP2C19 enzyme. This pharmacokinetic interaction results in increased systemic exposure for several co-administered drugs that are metabolized by this pathway, such as Diazepam and Phenytoin, and the antiplatelet drug Clopidogrel, for which the anti-platelet activity may be diminished.

A major pharmacodynamic interaction is driven by Omeprazole's effect on gastric pH. By raising the stomach pH, Omeprazole reduces the absorption and subsequent bioavailability of medicines that require an acidic environment, including Ketoconazole, Itraconazole, and Iron salts. A population-specific interaction caution notes that the risk of increased Tacrolimus levels is heightened for patients identified as CYP2C19 intermediate or poor metabolizers.

Procedural Constraint

A procedural constraint exists for diagnostic testing: Omeprazole must be temporarily stopped for at least 14 days prior to assessing Chromogranin A levels to prevent a falsely elevated result.

Mechanism of Action

How Inpro Works

Inpro's mechanism, driven by Omeprazole, is defined by highly selective and irreversible enzyme inhibition. The drug functions as an acid-activated prodrug, meaning it is largely inactive until it concentrates and converts to its active sulfenamide form within the extremely acidic canaliculi (pH < 4) of the stomach's parietal cells.

This active metabolite then forms a permanent covalent bond with specific cysteine residues on the H^+/K^+-ATPase enzyme (the Proton Pump), the critical enzyme responsible for the final step of acid secretion. The resulting irreversible inhibition of the pump halts the extrusion of hydrogen ions ( H^+) into the stomach lumen. This sustained duration of effect is maintained because the parietal cell must synthesize and insert new, functional enzyme proteins to restore acid-secreting capacity, a process that determines the recovery time and leads to a prolonged reduction in the concentration of hydrogen ions.

Dosage and Administration Information

General Principles of Administration

Inpro is administered via the oral route as delayed-release capsules or tablets, or via intravenous (IV) infusion when oral intake is not possible. To ensure proper use, oral forms must be swallowed whole and must not be crushed or chewed, as this preserves the integrity of the delayed-release formulation necessary for its action. If the oral solid cannot be swallowed, the contents of the capsule may be opened and mixed with a spoonful of soft, cool applesauce for immediate consumption.

Dosing and Contextual Use

Standard adult regimens for initial treatment typically involve taking 20 mg or 40 mg once daily. Doses required for hypersecretory conditions may be higher, and any daily dose exceeding 80 mg must be administered in divided doses. For optimal action, oral administration is required to be taken before a meal, ideally in the morning. Treatment generally consists of a short-term course of 4 to 8 weeks for healing or a defined longer-term regimen for maintenance.

While no dose adjustment is typically needed for impaired renal function, a reduction, such as 10 mg once daily, may be appropriate for patients with hepatic impairment. The intravenous powder for infusion requires reconstitution and is given over 20 to 30 minutes in a clinical setting. If a dose is missed, it should be taken as soon as remembered, but never take two doses at once to catch up.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Inpro

Evidence for Healing of Erosive Esophagitis (EE)

The evidence base for Inpro in managing erosive esophagitis, a condition for which the research examined outcomes related to the injury of the esophageal lining associated with acid reflux, is largely drawn from extensive randomized controlled trials (RCTs). These are research studies where patients are randomly assigned to a specific research protocol, such as receiving Inpro. The research primarily examined the repair process, with key outcomes related to mucosal status, which is the integrity of the tissue lining.

Studies were conducted during periods of increased symptom activity and were typically short-term, with a focus on acute healing measured over periods lasting about 4 to 8 weeks. Research also explored outcomes related to whether the condition returned, or relapsed, during periods when the medicine was continued over maintenance periods of up to a year.

Evidence for Managing Reflux Symptoms (GERD/NERD)

Inpro was evaluated in numerous short-term trials designed to understand outcomes related to managing the common symptoms of reflux disease, including both symptomatic GERD and Non-Erosive Reflux Disease (NERD). These placebo-controlled RCTs examined symptom intensity and frequency by tracking patient-reported outcomes describing perceived discomfort across short defined time intervals, often lasting around 4 weeks. Studies monitored outcomes reflecting daily functioning and outcomes related to systemic or functional imbalance, such as the pH level inside the stomach.

For patients diagnosed with Non-Erosive Reflux Disease (NERD), which is a condition characterized by fluctuating or episodic manifestations, findings were observed in some studies to be more varied or less consistent than those for patients with visible mucosal injury. Since trials focused on symptom relief are generally short, the follow-up durations were limited.

What is Still Uncertain About Inpro's Research

There is limited information for long-term outcomes that extend beyond the typical maintenance period of one year. The full characterization of very long-term effects is primarily tracked in observational settings and derived from longitudinal data, rather than being established by controlled trials.

In addition, the comparative evidence is lacking for the active ingredient's use in the non-acidic indications (prostate comfort, tissue support) mentioned in some product information. In these areas, dedicated research is limited, and evidence quality varies across studies. Furthermore, while data exists for children, subgroup findings are uncertain for the youngest age groups.

Frequently Asked Questions (FAQ)

Common questions about Inpro (FAQ)


Q: What is Inpro used to treat specifically?

Official product labeling indicates that Inpro is used for the short-term treatment of specific acid-related conditions, including active ulcers in the stomach and small intestine, symptomatic GERD, and healing erosive esophagitis. It is also used in combination with antibiotics to eradicate H. pylori bacteria and for managing pathological hypersecretory conditions.


Q: Is Inpro approved for long-term use?

Treatment for most indications, such as active ulcers, is typically short-term, lasting only four to eight weeks. However, official documents indicate that the medicine may be used for maintenance of erosive esophagitis healing for up to 12 months. Certain rare conditions, known as pathological hypersecretory conditions, may require use for a longer period of time.


Q: What population groups is Inpro typically prescribed for?

Regulatory agencies have approved the medicine for use in adults and in pediatric patients over the age of one year. It is prescribed for specific acid-related diseases like symptomatic GERD, erosive esophagitis, and the management of ulcers associated with H. pylori infection.


Q: Is Inpro safe for people who are over 65 years old?

According to official prescribing information, no dose adjustment is routinely necessary based on age alone for older adults. However, a specific warning notes that the risk of serious side effects, such as inflammation or tearing of a tendon, is increased in patients over 60 years of age.


Q: How long after starting Inpro should I expect to see improvement?

Studies indicate that the medicine begins working to reduce acid within one hour of administration. Clinical data suggests that initial symptom relief may be noticed within the first day, and the full acid-suppressing effect is typically reached within four days of consistent use.


Q: Does Inpro affect sleep patterns?

Official product information lists insomnia (difficulty falling or staying asleep) as a reported side effect. The medication is associated with these kinds of sleep disturbances.


Q: Can Inpro be taken by people with diabetes?

The official safety profile notes that the medication has been associated with disturbances in blood glucose, leading to both high or low blood sugar levels. This reported adverse reaction is relevant information for individuals who manage or monitor their blood glucose.


Q: What does the patient information leaflet say about Inpro and driving?

Regulatory-sourced patient information indicates that the medication will not usually impair a patient's ability to drive or operate machinery. If side effects such as dizziness or drowsiness occur, official guidance indicates that activities requiring alertness, such as driving or operating machinery, should be avoided.


Q: Are the side effects of Inpro permanent?

Common side effects, such as headache or stomach pain, are generally temporary and typically resolve within a few days or weeks of treatment. While rare, the serious adverse reactions noted in the warnings carry a risk of being long-lasting or potentially irreversible.


Q: How does taking Inpro affect blood test results?

Taking Inpro long-term may lead to reduced levels of Vitamin B-12 and magnesium, which can be detected during routine blood testing. Additionally, a procedural constraint requires temporarily stopping the medicine for at least 14 days before assessing certain hormone levels, such as Chromogranin A.


Q: Can Inpro be taken with over-the-counter pain medication?

Regulatory information indicates that it is generally considered safe to take Inpro with common over-the-counter pain relievers, such as paracetamol (acetaminophen) or ibuprofen. The medicine is sometimes used to protect the stomach lining when a patient is taking certain anti-inflammatory drugs.


Q: Does Inpro have a generic version available?

Yes, the active ingredient in Inpro is Omeprazole, which is widely available in generic form.


Q: Can Inpro cause changes in weight?

Official safety information includes reports of changes in weight, specifically rapid or unusual weight gain, as an uncommon side effect.


Q: Does Inpro make you feel drowsy or tired?

Reported side effects of the medication include dizziness and drowsiness. Official documents also mention unusual tiredness or weakness among the reported reactions.


Q: Can Inpro be taken with blood pressure medicine?

Omeprazole inhibits a liver enzyme called CYP2C19. This means that taking Inpro may potentially change the concentration of other medicines, including some blood pressure medications, that are metabolized by this same enzyme pathway. This potential interaction is a key consideration when reviewing the full medication profile.


Q: Is Inpro considered a dependence-forming medication?

Inpro is not chemically classified as an addictive or dependence-forming medication. However, stopping the drug suddenly may lead to temporary symptoms of rebound acid hypersecretion (increased acid production) which can mimic the need for the drug.


Q: How long does Inpro stay in your system after stopping it?

According to clinical pharmacology studies, the drug is rapidly eliminated from the bloodstream. Its elimination half-life is approximately one hour, and it is almost entirely cleared from the plasma within 3 to 4 hours after a dose.


Q: What happens if a person accidentally takes too much Inpro?

Reported symptoms following an accidental overdose have included temporary effects such as blurred vision, confusion, headache, dry mouth, and drowsiness. Official information indicates that these symptoms typically resolve with supportive care.


Q: Is Inpro approved in countries outside of the US?

Yes, the active ingredient in Inpro, Omeprazole, is approved and regulated for use by major governmental bodies in countries outside of the US, including those in Europe.

How should Inpro be stored and disposed of?

Storage Conditions

Inpro (Omeprazole) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication is highly sensitive to moisture and must be protected from humidity. Official regulatory labeling requires that the product be kept in its original container, which must be tightly closed to maintain product stability and protect the contents. It is mandatory that Inpro must not be refrigerated and must not be frozen.

Child Safety and Disposal

All medicine must be stored out of the sight and reach of children. When discarding expired or unused Inpro, disposal should be done via an official drug take-back program or community collection site. This prevents contamination of the aquatic environment. Medication should not be thrown into the household trash or flushed down the toilet unless local regulations explicitly permit it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inpro found in:

A-Z Index: